Hair-Loss Treatments, Ranked by the Evidence

What actually works for hair loss?

For pattern hair loss — the gradual thinning that affects most people who lose hair — a small set of treatments has genuine meta-analytic support, and a much larger set does not. Systematic-review evidence supports topical minoxidil, oral finasteride, and low-level laser therapy as treatments that promote hair growth in men with pattern loss, and finds minoxidil effective in women as well 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.. Everything else ranks below that line.

Ranking honestly means separating three tiers. The strongest tier is minoxidil and finasteride, the latter backed by long-term data 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.2Ref 2Kaufman KD, Rotonda J, Shah AK, Meehan AG (2008).Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia.Long-term (five-year) oral finasteride markedly decreases the likelihood of developing further visible hair loss versus placebo in men with pattern loss, supporting the maintenance framing and the durability of the top-tier ranking.. A middle tier — platelet-rich plasma and light therapy — shows benefit but with inconsistent study quality 3Ref 3Gupta AK, Bamimore MA, Foley KA (2020).Efficacy of non-surgical treatments for androgenetic alopecia: platelet-rich plasma systematic review and meta-analysis.Platelet-rich plasma improves hair density and thickness in androgenetic alopecia, but with heterogeneity and variable protocol quality across studies — the basis for placing PRP in a promising-but-inconsistent tier.1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.. The bottom tier is the crowded market of supplements and gadgets, which rides mostly on marketing. Before any of that ranking applies, though, the cause of the loss has to be identified correctly, because the whole ranking is for one specific diagnosis.

First: is it pattern loss or something else?

The evidence ranking here is for androgenetic alopecia — pattern hair loss — and applying it to the wrong diagnosis wastes months. Two common look-alikes behave differently. Telogen effluvium is diffuse shedding triggered by illness, stress, or childbirth, and often recovers on its own. Alopecia areata is an autoimmune condition in which the immune system attacks the hair follicles, producing patchy loss with an unpredictable course 4Ref 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, typically causing patchy loss with an unpredictable course; treatments can promote regrowth but there is no cure — supporting the distinction from pattern hair loss..

The distinction matters because the treatments do not transfer. Understanding alopecia areata vs pattern loss is the pivot: alopecia areata versus androgenetic is a different disease driven by a different mechanism, so alopecia areata vs male pattern baldness is not a matter of degree but of biology 4Ref 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, typically causing patchy loss with an unpredictable course; treatments can promote regrowth but there is no cure — supporting the distinction from pattern hair loss.. Sudden patchy loss, well-defined bald circles, or thinning with scaling or scarring are signals that this is not ordinary pattern thinning and warrants a clinician's diagnosis before any treatment is chosen.

Other causes round out the picture, and each points somewhere different. Traction alopecia comes from tight, repeated pulling — braids, extensions, tight ponytails — and often eases when the tension does. Thyroid disease, iron deficiency, and certain medications can all thin hair as well. Because these have their own fixes, chasing them with a pattern-loss product misses the actual problem, which is the whole reason a diagnosis precedes the ranking rather than following it.

The evidence, tiered

Laid out by strength of evidence rather than by how heavily a product is advertised, the landscape sorts cleanly. The table below reflects what systematic reviews support for pattern hair loss: a well-supported top tier, a mixed middle, and a poorly supported bottom. Strength of evidence is not the same as size of effect — even the best options are maintenance, not cure.

the useful split is not brand versus brand but evidence tier versus evidence tier — start at the top and work down.

The best-supported tier: minoxidil and finasteride

Two treatments anchor the top tier. Topical minoxidil promotes hair growth and is the single option with review-level support in both men and women 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.. Oral finasteride, used in men, also promotes growth, and long-term analysis shows it decreases the likelihood of developing further visible hair loss over five years compared with placebo 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.2Ref 2Kaufman KD, Rotonda J, Shah AK, Meehan AG (2008).Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia.Long-term (five-year) oral finasteride markedly decreases the likelihood of developing further visible hair loss versus placebo in men with pattern loss, supporting the maintenance framing and the durability of the top-tier ranking.. These are the closest things to reliable in pattern hair loss.

There is a real split by sex here. Finasteride is a men's-pattern-loss treatment in this evidence base and is generally not used in women who could become pregnant, which is where the hair loss treatment by sex divergence begins — the antiandrogen contraindication between men and women shapes the whole plan. Minoxidil crosses that line and works in female pattern loss too 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.. For female pattern thinning, clinicians often add an oral antiandrogen such as spironolactone; spironolactone for women's hair thinning is covered separately, and the female vs male pattern treatment paths branch from there. Neither drug carries a dose you should infer from this page — those decisions belong with a prescriber.

One honest caveat about the top tier: 'strongest evidence' describes reliability, not magnitude. Even minoxidil and finasteride typically slow, hold, or partially reverse loss rather than restore a full head of hair, and how much they do varies between people. Ranking them first means they are the most dependable place to start, not that they guarantee a dramatic result — a distinction the marketing around every tier tends to blur.

The promising-but-inconsistent tier: PRP, lasers, and microneedling

Below the top tier sits a group with real but shakier evidence. Platelet-rich plasma — injecting a concentrate of a person's own platelets into the scalp — improves hair density and thickness in pattern loss according to meta-analysis, but the same analysis flags heterogeneity and variable protocol quality across studies, so results are less predictable than the top tier 3Ref 3Gupta AK, Bamimore MA, Foley KA (2020).Efficacy of non-surgical treatments for androgenetic alopecia: platelet-rich plasma systematic review and meta-analysis.Platelet-rich plasma improves hair density and thickness in androgenetic alopecia, but with heterogeneity and variable protocol quality across studies — the basis for placing PRP in a promising-but-inconsistent tier.. Low-level laser therapy has meta-analytic support for growth in men and sits at the boundary of this tier and the one above 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss..

Scalp microneedling belongs here too, usually studied as an add-on rather than a stand-alone treatment. Whether microneedling works for hair growth is an open, early question, and scalp microneedling for hair loss is most often paired with minoxidil in the small studies that exist rather than tested alone. The honest read on this whole tier is that it may add benefit for some people, but the evidence is not yet strong enough to rank any of it alongside minoxidil and finasteride.

There is a pattern worth noticing as you move down from the top tier: cost and invasiveness tend to climb while the certainty of benefit falls — the opposite of what a shopper hopes for. That trade-off deserves to be named plainly. The more a treatment costs, and the more it is marketed as cutting-edge, the more reasonable it is to ask to see the trial evidence before committing money to it.

Where the money mostly goes: supplements and gadgets

The largest, loudest part of the hair-loss market is also the least supported. Direct-to-consumer supplements, thickening serums, and at-home gadgets are marketed hard, but the treatments with actual meta-analytic backing are minoxidil, finasteride, and low-level laser therapy 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss. — and most of what fills the supplement aisle is not among them. That gap between marketing volume and evidence is the entire reason to rank by proof rather than by packaging.

This does not mean a supplement can never help a genuine deficiency; it means the blanket 'hair growth' claims on most bottles are not built on strong trials. The same evidence-first lens is worth bringing to any cosmetic claim — whether skincare gadgets and supplements work at all, or whether cellulite treatments actually work — because gadgets, gua sha, and pills tend to be sold on hope rather than data. Spending in this tier is optional; spending on the top tier is where the evidence actually points.

How to read a hair-loss product claim

Because the market outruns the evidence, a little label-reading goes a long way. The most useful question about any hair product is not whether it has testimonials or before-and-after photos — those are marketing, not evidence — but whether its active ingredient is one that controlled trials support. Minoxidil, finasteride, and low-level laser therapy clear that bar for pattern loss 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.; a proprietary blend with a long ingredient list and no trial usually does not.

A few patterns signal a weak claim. Language like 'supports healthy hair' rather than 'grows hair' is doing careful legal work around the lack of proof. Results shown only in photos, with no trial behind them, are anecdote. And 'clinically tested' without saying what the test found, or whether it beat a placebo, means very little. None of this proves a given product useless, but each moves it into the unproven tier — where the honest stance is caution about spending. Asking 'what actually beat placebo?' is the single most protective habit a shopper can bring to this whole category.

Alopecia areata is a different track

For alopecia areata, the ranking above does not apply, because the condition is autoimmune rather than hormonal. The immune system attacks the hair follicles, causing patchy loss with an unpredictable course; treatments can promote regrowth, but there is no cure 4Ref 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, typically causing patchy loss with an unpredictable course; treatments can promote regrowth but there is no cure — supporting the distinction from pattern hair loss.. The options are genuinely different from pattern-loss care, and treating one as if it were the other leads nowhere.

The biggest recent change is systemic JAK inhibitors. Two phase 3 trials showed that oral baricitinib, a JAK inhibitor, produced significantly more hair regrowth than placebo in adults with severe alopecia areata, and the results became the basis for the first systemic treatment approved for the condition 5Ref 5King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.The BRAVE-AA1 and BRAVE-AA2 phase 3 trials showed oral baricitinib (a JAK inhibitor) produced significantly more hair regrowth than placebo in adults with severe alopecia areata, the basis for the first systemic approval in the condition.. That is a meaningful advance for severe disease, though it applies to alopecia areata specifically and not to ordinary pattern thinning. Anyone facing sudden, patchy loss is better served by a diagnosis than by reaching for a pattern-loss product off the shelf.

Systemic drugs are not the first move for milder disease. For limited, patchy alopecia areata, other treatments — including injections into the patches and topical measures — are typically used before systemic medication, and some patches regrow on their own given the condition's unpredictable course 4Ref 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, typically causing patchy loss with an unpredictable course; treatments can promote regrowth but there is no cure — supporting the distinction from pattern hair loss.. The systemic option matters most when the loss is extensive or resistant, which is another reason the diagnosis, and how much scalp is involved, drives the plan more than any single product does.

What to expect: timelines and sticking with it

Two expectations keep people from quitting too early or hoping for too much. First, hair treatments work slowly — regrowth and thickening are measured across months, not weeks, because the hair cycle itself is slow. Second, the supported pattern-loss treatments are maintenance: their benefit depends on continuing them. Long-term data on finasteride show it keeps decreasing the likelihood of further visible loss across years of continued use 2Ref 2Kaufman KD, Rotonda J, Shah AK, Meehan AG (2008).Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia.Long-term (five-year) oral finasteride markedly decreases the likelihood of developing further visible hair loss versus placebo in men with pattern loss, supporting the maintenance framing and the durability of the top-tier ranking..

The corollary is that stopping generally lets pattern loss resume, because the underlying process was being held in check rather than reversed 1Ref 1Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Minoxidil, finasteride, and low-level laser therapy promote hair growth in men with androgenetic alopecia, and minoxidil is effective in women — the basis for the top and supported tiers of the evidence ranking for pattern hair loss.2Ref 2Kaufman KD, Rotonda J, Shah AK, Meehan AG (2008).Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia.Long-term (five-year) oral finasteride markedly decreases the likelihood of developing further visible hair loss versus placebo in men with pattern loss, supporting the maintenance framing and the durability of the top-tier ranking.. That is worth knowing before starting, so the commitment is a clear-eyed one rather than a surprise later. And if the loss is patchy, sudden, scarring, or accompanied by other symptoms, a dermatologist's diagnosis comes before any of this — the ranking here is only for pattern loss, and the wrong diagnosis makes even the best-ranked treatment useless.

One more expectation smooths the road: some treatments cause an early, temporary shed as the hair cycle resets — a jarring sight that leads people to quit just before the benefit appears. Knowing it can happen keeps a normal part of the process from being mistaken for failure. Judged at the scale of months rather than weeks, and continued steadily, the supported treatments are given a fair chance to show what they can do.